TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
TG Therapeutics (TGTX) PT Raised to $36 at SunTrust Robinson Humphrey; Catalyst Rich 6-18 Months
November 9, 2017 7:47 AM ESTSunTrust Robinson Humphrey raised its price target on TG Therapeutics (NASDAQ: TGTX) to $36.00 (from $28.00) while maintaining a Buy rating.
Analyst Suneja Yatin sees the next 6-18 months are a catalyst-rich period for TGTX, with multiple N-T inflection points: (1) UNITY-CLL pivotal ORR... More
